1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

TMC Bets Dosing Convenience, Field Force Synergies Will Help Oritavancin Prosper

 
• By Michael Goodman

The Medicines Co. held an analyst meeting Oct. 9 in large measure to broadcast the progress it has made diversifying away from its current chief revenue generator, the cardiovascular drug Angiomax. It’s betting that its first foray into antibiotics, the IV-administered drug oritavancin, will best competition because of dosing advantages, efficacy, and the sponsor’s deep expertise in the tumultuous hospital market

Oritavancin, The Medicines Co.’s first foray into the tricky world of hospital antibiotics, stands to benefit against the competition, including a widely used standard of care that is generic, through its efficacy, dosing convenience, and ability to save hospital customers money, TMC management told analysts at the company’s investor meeting on Oct. 9. The drug can help hospitals improve the quality of their care at a time when the federal government is increasingly holding them accountable for meeting certain standards, while reducing costs.

Oritavancin recently completed two Phase III clinical trials, SOLO I and SOLO II, comparing it favorably to vancomycin, the current...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

Part B Negotiation Proposal Would Lower Prices In MA, Private Plans Too, Stakeholders Complain

 
• By Cathy Kelly

The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

More from Market Access

UK’s Plan To Become World’s Third Top Life Sciences Economy Falls Short, Says ABPI

 
• By Neena Brizmohun

The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.

Spain’s Medicines Shortages Plan Clears Administrative Hurdles For Essential Medicine Manufacturers

 
• By Francesca Bruce

A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 
• By Neena Brizmohun

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.